The Synergistic Inhibitory Effect of Combining MK-2206 and AZD 6244 in MARIMO Cells Harboring a Calreticulin Gene Mutation
Authors:
- 19 October 2021
- journal article
- research article
- Published by S. Karger AG in Chemotherapy
- Vol. 66 (5-6) , 169-178
Abstract
Introduction: Somatic mutations in the calreticulin (CALR) gene occur in most myeloproliferative neoplasm (MPN) patients who lack Janus kinase 2 or thrombopoietin receptor (MPL) mutations, but the molecular pathogenesis of MPN with mutated CALR is unclear, which limited the further treatment for CALR gene mutant patients. Objectives: Previous studies showed that CALR mutations not only activated serine/threonine protein kinase (AKT) in primary mouse bone marrow cells but also mitogen-activated protein kinases (MAPKs) in MARIMO cells harboring a heterozygous 61-bp deletion in CALR exon 9, which were responsible for mutant CALR cell survival, respectively. Hence, we aimed to initially explore the mechanism of AKT activation and observe the synergistic inhibitory effect of combining AKT (MK-2206) and MAPK kinase (AZD 6244) inhibitors in MARIMO cells. Methods: We detected the expression of phosphorylated AKT in MARIMO cells treated with inhibitors for 24 or 48 h by western blotting and analyzed cell proliferation, cell cycle, and apoptosis by flow cytometry. We further examined the synergistic inhibitory effect of combining MK-2206 and AZD 6244 in MARIMO cells using the median effect principle of Chou and Talalay. Results: We found that the AKT was activated in MARIMO cells, and blocking its activity significantly inhibited MARIMO cell growth with downregulation of cyclin D and E, and accelerated cell apoptosis by decreasing Bcl-2 but increasing Bax and cleaved caspase-3 levels in a dose-dependent manner. Further analysis showed that AKT activation was dependent on mammalian target of rapamycin but not on the JAK signaling pathway in MARIMO cells, displaying that inhibition of JAK activity by ruxolitinib (RUX) did not decrease the AKT phosphorylation. Furthermore, the combination of MK-2206 and AZD 6244 produced a significantly synergistic inhibitory effect on MARIMO cells. Conclusions: AKT activation is a feature of MARIMO cells and co-targeting of AKT and MAPKs signaling pathways synergistically inhibits MARIMO cell growth.Keywords
This publication has 35 references indexed in Scilit:
- Cholesterol depletion by methyl-β-cyclodextrin augments tamoxifen induced cell death by enhancing its uptake in melanomaMolecular Cancer, 2014
- From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasmsBlood, 2014
- CALR mutations in myeloproliferative neoplasms: Hidden behind the reticulumAmerican Journal of Hematology, 2014
- Somatic Mutations of Calreticulin in Myeloproliferative NeoplasmsNew England Journal of Medicine, 2013
- AKT is a therapeutic target in myeloproliferative neoplasmsLeukemia, 2013
- Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AMLBlood, 2006
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR ComplexScience, 2005
- Megakaryocyte proliferation and ploidy regulated by the cytoplasmic tail of glycoprotein IbαBlood, 2004
- Calreticulin is essential for integrin-mediated calcium signalling and cell adhesionNature, 1997
- CalreticulinCell, 1997